Safety and Efficacy Study in Infant With SBS

NCT02865122 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision based on enrollment

Conditions

Short Bowel Syndrome

Interventions

DRUG: NTRA-9620
DRUG: Placebo

Sponsor

Elgan Pharma Ltd.